The Diabetic II Neuropathy and the Gene Polymorphism in the P636 Temperature Regulations

Abstract: A significant role for multigenetic predisposition in the development of diabetic nephropathy (DN) coheres with considerable variation in the incidence and prevalence of DN. Some of the genes that are likely involved in the development of diabetic nephropathy also control blood pressure, familial hyperlipidemia, familial hypertension, and other cardiovascular illnesses. The insertion/deletion polymorphism in the angiotensin-converting enzyme gene, the G/T polymorphism in the glucose transporter 1 gene, the G/T (894) polymorphism, and the T/C (-786) polymorphism in the eNOS gene were all examined in three groups of patients with diabetes mellitus to see if they were associated with diabetic nephropathy, non-diabetic nephropathy.

Key words: eNOS polymorphism, ACE polymorphism, Type 2 diabetes, Metabolic syndrome, Ray syndrome.
1. Introduction

Diabetic nephropathy (DN) is a kidney condition that worsens with time and is brought on by capillary angiopathy in the kidney glomeruli. The earliest change in the progression of diabetic nephropathy is microangiopathy. The condition known as "microalbuminuria" occurs when the kidneys start to eliminate more serum albumin than is typical. Nephromegalia is another prominent characteristic of the early diabetic kidney. An increase in the filter fraction and renal plasmatic flow are signs of glomerular hyperfiltration in the early stages, although the hypertrophic glomeruli still have a normal shape. Nodular glomerulosclerosis causes the diabetic nephropathy to worsen as more and more glomeruli are damaged.

Glomerulosclerosis-related hemodynamic changes result in reduced blood flow, decreased renal function followed by renal insufficiency, and the development of hyperlipidemia, elevated blood pressure, and hyperglycemia, especially when hyperglycemia is poorly controlled [1-3].

About one-third of diabetic people acquire end-stage renal disease, and there is a significant ethnic variation in the incidence and prevalence of DN [4]. Numerous epidemiologic studies have demonstrated another component of genetic predisposition, showing that the cumulative risk is approximately 50% higher in families with members who have DN than in families without DN [4-6]. The variation fits with a significant role for multigenetic predisposition in DN development. Several genes that likely play a role pathogenesis of DN, have been investigated. Those genes also play a role in the regulation of blood pressure, familial hyperlipidemia, familial hypertension and other diseases of the cardiovascular system. The gene for angiotensin-converting enzyme (ACE) is highly studied, because it contains very well characterized polymorphism I/D - insertion and deletion [7]. Allele D is associated with a higher expression of ACE; increased synthesis of ACE is probably the cause of the initialisation and the progression of diabetic nephropathy [8] and the IgA nephropathy [9]. Further fifteen polymorphisms have been described in the gene for angiotensinogen, but only two of them have been associated with mechanisms of hypertension [7,10]. Other described mutations are the G/T polymorphism in the glucose transporter 1 gene [11,12], the mutation in the atrial natriuretic peptide gene [13], the C/T (-106) polymorphism in the gene for aldose reductase [14], the polymorphisms in the nuclear factor kappa B gene [15], the G/T (894) and T/C (-786) polymorphisms in the endothelial nitric oxide synthase (eNOS) gene, variable number of tandem repeats in intron 4 (4a/4b) in the eNOS gene [16] and the polymorphism Ser/Leu in the inducible nitric oxide synthase gene (iNOS) [17].

We have studied polymorphisms (G/T (894) in the exon 7 and T/C (-786) in the promoter) in the eNOS gene, I/D polymorphism in the ACE gene and G/T polymorphism in the GLUT1 gene in three groups of patients with type 2 diabetes: patients without diabetic nephropathy (the DM group), patients with diabetic nephropathy (the DN group) and patients with non-diabetic renal disease (the NDRD group). Our objective was to determine whether the selected polymorphisms, which have been identified as a risk factor for diabetic nephropathy, are associated with the etiology of hypertension, diabetic nephropathy, nephropathy of non-diabetic origin or type 2 diabetes itself.

2. Experimental Procedures

2.1 Database

A database of Czech and German type 2 diabetic patients (342) and control healthy subjects (114) were tested for I/D polymorphism in the ACE gene, G/T polymorphism in the GLUT1 gene, G/T (894) and T/C (-786) polymorphisms in the eNOS gene. The diagnosis of diabetes mellitus was determined according to American Diabetes Association (ADA) criteria [18]. Patients were separated into three groups, the DM group of diabetic patients without diabetic nephropathy, the DN group of diabetic patients with diabetic nephropathy and the NDRD group of diabetic patients with non diabetic renal disease. The study was approved by the Ethical Committee of the Third Faculty of
The group of diabetic patients without nephropathy (DM, n=117) was formed by patients fulfilling following criteria: 1) duration of DM as minimum as 5 years; normoalbuminuria (i.e. <30 mg/24-hrs) or albumin/creatinine <22.8 mg/mmol in morning urine sample; 2) normal values of renal function assessed by serum creatinine level <115 μmol/l for men and <110 μmol/l for women, respectively; 4) normal urinary sediment. The presence of diabetic nephropathy (DN, n=149) was defined according to following criteria: 1) presence of the albumin/creatinine ratio ≥300 mg/g in two of three morning urine samples, or microalbuminuria ≥30 mg/24-hrs or proteinuria ≥500 mg/24-hrs; 2) normal kidney size on ultrasound examination performed recently; 3) duration of DM as minimum as 5 years. The third group (NDRD, n=76) was composed of diabetic patients with the presence of nephropathy of non-diabetic origin. The most prevalent NDRD (>85%) was atherosclerotic renal disease and the others were represented by chronic tubulointerstitial nephritis (12%) or others.

The presence of tubulointerstitial nephritis was defined according to following criteria: history of repetitive UTI (urinary tract infection), leukocyturia in urinanalysis, low grade proteinuria (proven as tubular origin) and negative signs of any glomerular disease, possibly decreased kidney size in ultrasound examination. The presence of hypertension was defined according to blood pressure above 140/90 mmHg or according to anykind of antihypertensive medication. Healthy individuals without any signs of nephropathy were used as a control group (n=114).

2.2 DNA analyses

DNA was extracted from the whole blood with EDTA by QIAamp DNA Blood Mini kits (Qiagen). The G/T (894) polymorphism in the eNOS gene was identified by PCR-RFLP method. The primers 5’-AAG GCA GGA AGT GGA TGG A-3’ (sense) and 5’-CCC AGT CAA TCC CTG TGG TGC TCA-3’ (anti-sense) amplified the 258-bp fragment encompassing the G1492A variant. The PCR reaction was performed with the annealing temperature at 64ºC [15,19]. PCR product was digested with the restriction enzyme Eco241 (Fermentas). The G allele (corresponding to a glutamic acid at position 298), digested, was characterized by two fragments of 163 and 85 bp in length. The T allele, minor (corresponding to an aspartic acid at position 298), non-digested, was characterized by the 248 bp fragment [19,20]. The T/C (-786) polymorphism in the eNOS gene was analyzed using PCR and RFLP methods. PCR reaction was performed using the primers 5’-GTG TAC CCC ACC TGC ATT CT-3’ (sense) and 5’-CCC AGC AAG GAT GTA GTG AC-3’ (antisense). The PCR reaction was performed with the annealing temperature at 60ºC [15,19]. PCR product was subjected to digestion with Turbo NaeI (Promega) [21,22]. The T allele was digested. The amplified fragment length polymorphism PCR method (AFLP) was used for the I/D polymorphism (intron 16) in the ACE gene. The primers 5’-GCC CTG CAG GTG TCT GCA GCA TGT-3’ (sense) and 5’-GGA TGG CTC TCC CCG CCT TCT TCT-3’ (antisense) were designed for detection of the I allele with a length of 597 bp and the D allele with a length of 319 bp. The PCR reaction was performed with the annealing temperature at 50ºC [15,23]. The G/T single nucleotide polymorphism in the GLUT1 gene was identified by PCR and RFLP methods. The primers 5’-TGT GCA ACC CAT GAG CTA A-3’ (sense) and 5’-CCT GGT CTC ATC TGG ATT CT-5’ (antisense) (Metabion International) were used to identify the gene. The PCR reaction with the annealing temperature at 30ºC [15,24] was followed by digestion with XbaI (Fermentas Life Sciences). The G allele, non-digested, was characterized by the fragment 1.1 kb long and the T allele, minor, digested, by the 0.2 and 0.9 kb long fragments. All the PCR and the restriction digest products were analyzed by electrophoresis in 3% agarose gel stained with ethidium bromide and compared to the molecular marker pUC19 (Fermentas Life Science).
2.3 Statistics

Statistic evaluation was performed using SamplePower 2.0, SPSS SamplePower 2.0 (USA) and SPSS 15.0 version (USA) program. A significant difference was assumed if the P-level was ≤0.05. The verification of genotype comparisons was performed by Chi-Square test for independency in contingency tables and the verification of allele comparisons by Chi-Square test for independency in contingency tables and Fisher’s exact test. Overall, the genotype distributions were consistent with Hardy-Weinberg equilibrium. The logistic regression analysis was used to examine relationship between the polymorphisms and diagnoses.

3. Results

All the characteristics of diabetic patients and healthy individuals such as gender, age, DM duration, laboratory results, occurrence of arterial hypertension and diabetic retinopathy are listed in Table 1. In all three groups, the DM group, DN group and NDRD group, were persons aged 65 and over, and both sexes. The DM group was used as a control group in comparison with the DN and NDRD groups. The group of healthy individuals without any signs of nephropathy was used as a control group in comparison with the diabetic groups.

Significant results (P=0.004, P=0.043, P=0.020, respectively) were found for the T/C eNOS polymorphism in the comparison of the genotype’s frequencies

<table>
<thead>
<tr>
<th>variable</th>
<th>patients without diabetic nephropathy</th>
<th>patients with diabetic nephropathy</th>
<th>patients with non-diabetic renal disease</th>
<th>healthy individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>number in group</td>
<td>117</td>
<td>149</td>
<td>76</td>
<td>114</td>
</tr>
<tr>
<td>age (years)</td>
<td>67.112 (SD=12.44)</td>
<td>70 (SD=13)</td>
<td>80 (SD=7.160)</td>
<td>45 (7.315)</td>
</tr>
<tr>
<td>DM duration (years)</td>
<td>24.649 (SD=13.187)</td>
<td>23 (SD=10.27)</td>
<td>23 (SD=8)</td>
<td>-</td>
</tr>
<tr>
<td>gender</td>
<td>males</td>
<td>88 males</td>
<td>44 males</td>
<td>77 males</td>
</tr>
<tr>
<td></td>
<td>females</td>
<td>61 females</td>
<td>32 females</td>
<td>37 females no</td>
</tr>
<tr>
<td>arterial hypertension</td>
<td>65 yes (56%)</td>
<td>119 yes (80%)</td>
<td>59 yes (78%)</td>
<td>&lt;0.15 g/24</td>
</tr>
<tr>
<td>diabetic retinopathy</td>
<td>29 yes (25%)</td>
<td>116 yes (78%)</td>
<td>15 yes (20%)</td>
<td>&lt; 0.03 g/24</td>
</tr>
<tr>
<td>U-Alb (g/24)</td>
<td>&lt; 0.0706 g/24</td>
<td>1.007 g/l (Med) 3.000 g/l (Med)</td>
<td>0.060 g/l (Med)</td>
<td>males females</td>
</tr>
<tr>
<td>DU-prot (g/24)</td>
<td>&lt; 0.03 g/24</td>
<td>265.96 (SD=192.06)</td>
<td>0.380 g/l (Med)</td>
<td>44-110 44-104</td>
</tr>
<tr>
<td>S-Cr (μmol/l)</td>
<td>106.24 (SD=39.988)</td>
<td>7.5 (SD=1.65)</td>
<td>163.268 (SD=54.977)</td>
<td>2.8-4%</td>
</tr>
<tr>
<td>HbA1C (%)</td>
<td>6 (SD=0.905)</td>
<td>8.013 (SD=2.19)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Characteristics of the Czech and German patients and control subjects. The measured lab values are in means, standard deviations and medians. DM = diabetes mellitus, U-Alb = Albuminuria, DU-Prot = amount of urinary protein in 24 h, S-Cr = Serum Creatinine, HbA1C = glycated haemoglobin, Med = median.

between the healthy individuals and the groups (DM, DN, NDRD, respectively) of diabetic patients (Table 2). Patients suffered from arterial hypertension in both the DM and NDRD groups. The comparison between arterial hypertensive patients and patients without hypertension embodied significantly (P=0.021) different frequencies of genotypes in the I/D ACE polymorphism (Table 3).

Borderline significant results (P=0.055) were demonstrated for the minor C allele in regression analyses of diabetic nephropathy, T/C eNOS polymorphism (both genotype and allele) and arterial hypertension. Similar borderline results (P=0.057) were proven in the case of non-diabetic nephropathy patients. The C allele may be associated with diabetic nephropathy and other diabetic
complications. Borderline significant frequencies of alleles (P=0.048) were found in the I/D ACE polymorphism in the comparison of the DM group and the DN group (Table 4).

4. Discussion

We studied the prevalence of four gene polymorphisms, which had previously been published in the context of diabetic nephropathy progression. We examined the I/D polymorphism in the ACE gene [25-32], the G/T polymorphism in the GLUT1 gene [24,33], the G/T (894) polymorphism and the T/C (-786) polymorphisms in the eNOS gene [17,20,34-36]. We studied type 2 diabetic patients which were stratified into the DM group, the DN group and the NDRD group.

The NO pathway is an important factor in hypertension, renal disease, inflammation and atherosclerosis [37]. It was demonstrated in previous studies that the T/C (-786) eNOS polymorphism is associated with diabetic nephropathy and end stage renal disease [16,36], diabetic retinopathy and diabetic macula edema [38,39], albuminuria [40], rheumatoid arthritis [41], acute coronary syndrome [42,43], coronary artery disease [44] essential and arterial hypertension [45,46], inflammation and atherosclerosis [37,47]. In our study, significant results appeared for the T/C eNOS polymorphism in the comparison with genotype’s frequencies between the healthy individuals and the groups (DM, DN, NDRD respectively) of diabetic patients. Additionally, borderline significant results appeared for the minor C allele in both nominal regression analyses of diabetic nephropathy. T/C eNOS polymorphism and arterial hypertension and in nominal regression analyses of non-diabetic renal disease, T/C eNOS polymorphism and arterial hypertension. Type 2 diabetes is a part of metabolic syndrome (Ray syndrome) that directly or indirectly initiates the process of atherogenesis. The metabolic syndrome includes hyperinsulinism with insulin intolerance, hypertension, hyperglycemia, visceral adipose tissue and atherogenic dyslipidemia [48-50].

**Table 2.** Comparisons of T/C eNOS genotypes between healthy individuals and diabetic patients without (DM) and with diabetic nephropathy (DN), with non-diabetic renal disease(NDRD).

<table>
<thead>
<tr>
<th>CROSSTABS OF GENOTYPES</th>
<th>PEARSON CHI-SQUARE (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T/C eNOS</td>
<td></td>
</tr>
<tr>
<td>controls (101)</td>
<td>44 32 25</td>
</tr>
<tr>
<td>DM (116)</td>
<td>41 61 14</td>
</tr>
<tr>
<td>controls (101)</td>
<td>44 32 25</td>
</tr>
<tr>
<td>DN (147)</td>
<td>48 70 29</td>
</tr>
<tr>
<td>controls (101)</td>
<td>44 32 25</td>
</tr>
<tr>
<td>NDRD (74)</td>
<td>20 38 16</td>
</tr>
</tbody>
</table>

**Table 3.** Comparison of ACE genotypes between diabetic patients with and without arterial hypertension.

<table>
<thead>
<tr>
<th>Crosstabs of arterial hypertension prevalence</th>
<th>Pearson Chi-Square (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE/ arterial hypertension</td>
<td></td>
</tr>
<tr>
<td>no (66)</td>
<td>24 26 16</td>
</tr>
<tr>
<td>yes (229)</td>
<td>39 107 44</td>
</tr>
</tbody>
</table>

**Table 4.** Comparison of I/D ACE alleles between diabetic patients without (DM) and with diabetic nephropathy (DN)

<table>
<thead>
<tr>
<th>Crosstabs of alleles</th>
<th>Fisher’s Exact Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/D ACE</td>
<td>D I</td>
</tr>
<tr>
<td>DM (116)</td>
<td>95 71</td>
</tr>
<tr>
<td>DN (147)</td>
<td>126 142</td>
</tr>
</tbody>
</table>

Published by “CENTRAL ASIAN STUDIES" http://www.centralasianstudies.org

Copyright (c) 2022 Author(s). This is an open-access article distributed under the terms of Creative Commons Attribution License (CC BY). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
majority of diabetic patients in our cohort suffered from arterial hypertension and obesity. We demonstrated the importance of the T/C eNOS polymorphism as a risk factor for metabolic syndrome (which includes also T2D). We have confirmed previously published association studies with insulin resistance [51,52], the features of metabolic syndrome and with type 2 diabetes [54].

The genotypic frequency of the I/D ACE polymorphism was found to be significantly different between arterial hypertensive patients and patients without hypertension. Rigat et al. [8] found that the I/D polymorphism correlated with the level of ACE in the plasma. The quantity of ACE in the plasma is two-fold higher for the DD genotype than for the II genotype while the ID genotype produces a level of ACE which is intermediate to the DD and II genotypes [8]. Our results are consistent with the conclusions of other scientific groups [55-57] which confirmed that the DD genotype (also ID+DD genotype) and the D allele is associated with an increased risk of hypertension [55-57] which confirmed that the DD genotype (also ID+DD genotype) and the D allele is associated with an increased risk of hypertension [55-57].

Borderline different frequencies of alleles were found for the I/D ACE polymorphism in the comparison of the DM group and the DN group. The conclusions of individual association studies of the I/D ACE polymorphism and nephropathy syndrome differ due to different ethnic background [4] and different dietary habits. The minor D allele was not associated with type 2 diabetic nephropathy in a European population [7, 58-62] and the results from our study confirmed this fact. On the contrary, the association was proven for type 2 diabetic patients from an Asian population [31,63-70] with the exception of four studies [71-74].

We found no association between diabetic nephropathy and the G/T polymorphism in the GLUT1 gene and the G/T (894) polymorphism in the eNOS gene. The conclusions of other association studies on this issue differ. Some studies suggest an increased incidence of minor T allele in the GLUT1 gene in the group of patients with diabetic nephropathy [75-77]. While, other studies have not found an association between G/T polymorphism in the GLUT1 gene and the progression of DN [78,79]. In Japanese and Korean populations the G/T (894) polymorphism in the eNOS gene has been demonstrated as a predisposing factor for End-Stage Renal Disease and for type 2 DN [80,81]. In contrast, for a cohort of West Africans and Mexican Americans in the USA this association was not demonstrated [82,83]. The conclusions of the studies were variable probably due to different ethnic backgrounds [4]. Further detailed research is needed to clarify all the issues concerning associations of polymorphisms mentioned above and diabetic nephropathy.

In conclusion, we found no association between diabetic nephropathy and the G/T polymorphism in the GLUT1 gene and the G/T (894) polymorphism in the eNOS gene. We confirmed no association between the minor D allele in the ACE gene and diabetic nephropathy. We also confirmed the effect of I/D polymorphism in the ACE gene on the development of hypertension. Finally, we demonstrated the importance of the T/C eNOS polymorphism as a risk factor for metabolic syndrome (which includes also T2D).

Acknowledgements

This study was financially supported by the Research program of Charles University in Prague: 262703/ SVV/2011.


Glu298Asp Polymorphism With End-Stage Renal Disease, Hypertension, 2002, 40, 535-540


49. Groop L.C., Insulin resistance, the fundamental trigger of type 2 diabetes, Diabetes Obes. Metab., 1999, 1, S1-7


63. Gohda T., Makita Y., Shike T., Kobayashi M., Funabiki K., Haneda M., et al., Association of the


68. Tomino Y., Makita Y., Shike T., Gohda T., Haneda M., Kikkawa R., et al., Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients, Nephron, 1999, 82, 139-144


74. Liu Z.H., Guan T.J., Chen Z.H., Li LS., Glucose transporter (GLUT1) allele (XbaI-) associated with nephropathy in non-insulin-dependent diabetes mellitus, Kidney Int., 1999, 55, 1843-1848


78. Tarnow L., Grarup N., Hansen T., Parving H.H., Pedersen O., Diabetic microvascular
complications are not associated with two polymorphisms in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian type 1 diabetic patients, Nephrol. Dial. Transplant. 2001, 16, 1653-1656


